Patents by Inventor David James Rawson
David James Rawson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120149679Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.Type: ApplicationFiled: February 20, 2012Publication date: June 14, 2012Inventors: Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
-
Patent number: 8153814Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.Type: GrantFiled: January 12, 2010Date of Patent: April 10, 2012Assignees: Pfizer Limited, Icagen, Inc.Inventors: Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
-
Publication number: 20120010207Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Applicant: PFIZER LIMITEDInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Marcel John De Groot
-
Publication number: 20120010182Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z1, Ra, Rb, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 8, 2011Publication date: January 12, 2012Applicants: ICAGEN INC., PFIZER LIMITEDInventors: Alan Daniel Brown, Marcel John De Groot, Brian Edward Marron, David James Rawson, Thomas Ryckmans, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West
-
Publication number: 20120010183Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Het1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Applicant: PFIZER LIMITEDInventors: Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Nigel Alan Swain, Steven Matthieu Gaulier
-
Publication number: 20100216823Abstract: The invention provides compounds of formula (I): wherein m, n, X, R1, A, B, R2 and R3 have the meanings given in the specification, and pharmaceutically acceptable salts, solvates, polymorphs and prodrugs thereof. The compounds are PDE7 inhibitors and have a number of therapeutic applications, particularly in the treatment of pain, especially neuropathic pain.Type: ApplicationFiled: May 16, 2008Publication date: August 26, 2010Inventors: David James Rawson, Nigel Alan Swain, Lesa Watson
-
Publication number: 20100197655Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.Type: ApplicationFiled: January 12, 2010Publication date: August 5, 2010Inventors: Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
-
Patent number: 7659305Abstract: The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.Type: GrantFiled: October 30, 2003Date of Patent: February 9, 2010Assignee: Pfizer Inc.Inventor: David James Rawson
-
Patent number: 7649004Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.Type: GrantFiled: July 12, 2005Date of Patent: January 19, 2010Assignee: Pfizer, Inc.Inventors: Charlotte Alice Louise Lane, Graham Nigel Maw, David James Rawson, Lisa Rosemary Thompson
-
Patent number: 7612226Abstract: The present invention relates to a method of treating pain using a compound of formula wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to certain novel derivatives of formula (I).Type: GrantFiled: April 28, 2006Date of Patent: November 3, 2009Assignee: Pfizer Inc.Inventors: Shelley Rene Graham, Simon John Mantell, David James Rawson, Jacob Bradely Schwarz
-
Publication number: 20080312235Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.Type: ApplicationFiled: July 12, 2005Publication date: December 18, 2008Inventors: Charlotte Alice Louise Lane, Graham Nigel Maw, David James Rawson, Lisa Rosemary Thompson
-
Patent number: 7084145Abstract: The invention provides compounds of formula (I), the pharmaceutically acceptable salts and solvates thereof, wherein A, B, R1, R2, and R7 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof as vasopressin V1A antagonists.Type: GrantFiled: October 24, 2003Date of Patent: August 1, 2006Assignee: Pfizer Inc.Inventors: Robert Duncan Armour, Andrew Douglas Baxter, Justin Stephen Bryans, Kevin Neil Dack, Patrick Stephen Johnson, Russell Andrew Lewthwaite, Julie Newman, David James Rawson, Thomas Ryckmans
-
Patent number: 7053122Abstract: The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.Type: GrantFiled: August 7, 2003Date of Patent: May 30, 2006Assignee: Pfizer IncInventors: Graham Nigel Maw, David James Rawson, Lisa Rosemary Thompson
-
Patent number: 6809200Abstract: A process is provide for the preparation of compounds of formula (I) herein comprising reacting a compound of formula (III), (IV) or (V) wherein the variables are as defined in the specification. The reaction is conducted in the presence of −OR3 and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent.Type: GrantFiled: July 26, 2001Date of Patent: October 26, 2004Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Keith Michael DeVries, Laurence James Harris, Philip Charles Levett, Joanna Teresa Negri, David James Rawson, Albert Shaw Wood
-
Publication number: 20040162278Abstract: The invention provides compounds of formula (I), 1Type: ApplicationFiled: October 24, 2003Publication date: August 19, 2004Applicant: Pfizer IncInventors: Robert Duncan Armour, Andrew Douglas Baxter, Justin Stephen Bryans, Kevin Neil Dack, Patrick Stephen Johnson, Russell Andrew Lewthwaite, Julie Newman, David James Rawson, Thomas Ryckmans
-
Patent number: 6770645Abstract: Compound of general formula I: wherein R1, R2, R3, R4, X, Y and R5 have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.Type: GrantFiled: March 12, 2002Date of Patent: August 3, 2004Assignee: Pfizer Inc.Inventors: Stephen Martin Denton, Mark Ian Kemp, Sandra Dora Newman, David James Rawson
-
Publication number: 20040138197Abstract: The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.Type: ApplicationFiled: August 7, 2003Publication date: July 15, 2004Inventors: Graham Nigel Maw, David James Rawson, Lisa Rosemary Thompson
-
Publication number: 20040132801Abstract: The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.Type: ApplicationFiled: October 30, 2003Publication date: July 8, 2004Inventor: David James Rawson
-
Patent number: 6756373Abstract: There is provided a compound of formula I: wherein X represents O or NR5 R4 represents H, halo, cyano, nitro, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13, NR16Y(O)R17, N[Y(O)R17]2, SOR18, SO2R19, C(O)AZ, lower alkyl, lower alkenyl, lower alkynyl, Het, alkylHet, aryl, alkylaryl (which latter seven groups are all optionally substituted with one or more substituents selected from halo, cyano, nitro, lower alkyl, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13 and SO2NR14R15) which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g., cGMP PDE5) is desired.Type: GrantFiled: October 6, 2000Date of Patent: June 29, 2004Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Graham Nigel Maw, David James Rawson
-
Publication number: 20040063643Abstract: Compounds of formula (I): 1Type: ApplicationFiled: April 28, 2003Publication date: April 1, 2004Applicant: Pfizer Inc.Inventors: Michael Higginbottom, Suzanne Ross Kesten, Russell Andrew Lewthwaite, Martyn Clive Pritchard, David James Rawson, Robert Michael Schelkun, Po-Wai Yuen